Protara Therapeutics Inc (NAS:TARA)
$ 5.51 0.01 (0.18%) Market Cap: 189.10 Mil Enterprise Value: 112.00 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 40/100

Protara Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 09:00PM GMT
Release Date Price: $5.1 (+2.00%)
Charles Zhu
Guggenheim Securities - Analyst

Hello, everyone, good afternoon. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities.

Our next fireside chat will be with Protara, and joining us here today is CEO, Jesse Shefferman. Jesse, thank you very much for taking the time to join us today. We really appreciate it. I guess just to kick us off, could you perhaps give us a two- or three-minute introduction of your company, your strategy, and your pipeline, and perhaps also since you are taking what seems to be a bit of a differentiated approach compared to many other biotechs out there.

Jesse Shefferman
Protara Therapeutics, Inc. - Co-founder, Director & CEO

Sure. Thanks, Charles, and thanks to the Guggenheim team for having me on. So Protara is a oncology and rare disease company. We have three programs under development right now, two of which are around our lead program, TARA-002. We'll get a little more detail on that in a bit.

But you talked about what is our differentiated approach. We are really good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot